| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T640 |
0-456 |
Sentence |
denotes |
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5. |
| T641 |
457-648 |
Sentence |
denotes |
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10. |
| T642 |
649-950 |
Sentence |
denotes |
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020 |
